It has been estimated that 1 in 5 adults suffer from pain and that another 1 in 10 adults are diagnosed with chronic pain each year. Apart from the acute pain associated with surgery or tissue damage, approximately 28 million adults in the UK live with chronic pain which markedly undermines quality of life, increases use of health resources and increases mortality.
Chronic pain is a term encompassing both inflammatory pain and neuropathic pain. Inflammatory pain is usually the result of neuronal injury which causes neurogenic inflammation such as that which causes low back pain or rheumatoid arthritis. Neuropathic pain is an intense, sharp, stinging or burning pain caused by damage to nerves or a disrupted nervous system.
To find out more about pain, visit our dedicated Learning Zone where world-leading experts suggest ways in which you can optimise pain management by combining careful assessment, employing non-pharmacological approaches and balancing the relative and absolute risks and benefits of each analgesic.
Related news and insights
Mesoblast announced results from the Phase III randomized controlled trial of its allogeneic mesenchymal precursor cell (MPC) therapy Revascor (rexlemestrocel-L) in 404 enrolled patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to conventional treatments.
Myovant Sciences and Pfizer Inc. announced that the Phase III SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss.
This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.
This guideline covers managing neuropathic pain (nerve pain) with pharmacological treatments (drugs) in adults in non-specialist settings. It aims to improve quality of life for people with conditions such as neuralgia, shingles and diabetic...
Certain miscellaneous idiopathic headache disorders, which are regarded as entities, are grouped in chapter 4 of the International Classification of Headache Disorders. Recent epidemiological research suggests that these headache...